Tag Archives: act

Akorn Tumbles On New Skin-Cream Rival From Actavis

Specialty drugmaker Akorn (AKRX) dropped more than 16% on the stock market today, near 43, after two analysts cut their price targets in the wake of a rival drug’s launch, even though Akorn affirmed its guidance. Sterne Agee and Jefferies cut their targets to 51 and 56, respectively, after Actavis (ACT) said late Monday that it was launching its own version of clobetasol, Akorn’s best-selling skin cream. “We estimate that post price increases in

Actavis Tops Views, Announces Name Change To Allergan

Shares of Actavis set a new high but then reversed direction in early trading Wednesday after the Irish drugmaker topped quarterly sales and profit views, helped by a big rise in sales of branded drugs. Actavis (ACT) also said that it will change its name to Allergan (AGN) after its $66 billion buyout of the Botox maker closes later this year. That deal, announced in November, is the third-biggest health care acquisition ever in the U.S.,

Actavis Leads IBD 50 Stocks With Earnings This Week

Earnings season is still chugging along past Presidents Day, with several major drugmakers and technology companies yet to disclose eagerly anticipated results. Today’s IBD 50 roundup takes a peek at two hot biotechs and one laser-focused tech firm reporting this week. Actavis (ACT) has already offered an early view of results. The Dublin-headquartered specialty pharmaceutical company hyped up Q4 figures last month when it said that its earnings